Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Drug Delivery
  4. Fast Track Articles
  5. Fast Track Article
image of Fabrication and Evaluation of Hyaluronic Acid-Coated Albumin Nanoparticles for Delivery of Gemcitabine

Abstract

Background

Gemcitabine (Gem) is a well-known antineoplastic drug used to treat several solid tumors. The clinical application of Gem is hampered owing to its non-selectivity, short half-life, and drug resistance, which, therefore, necessitate the development of a suitable novel formulation that can selectively target cancer sites.

Methods

In present work, Gem-loaded bovine serum albumin nanoparticles (Gem-BSANPs) have been prepared by using the desolvation cross-linking method and coated with hyaluronic acid (HA-Gem-BSANPs) to target the CD44 receptor which overexpressed on several solid tumors. The developed NPs were characterized by particle size, zeta potential, Transmission Electron Microscopy (TEM), and Differential Scanning Calorimetry (DSC). Further anticancer activity of the developed formulation was evaluated against A549 and MCF-7 cells and explored mode of action studies.

Results

The mean particle size and zeta potential of HA-Gem-BSANPs were observed as 144.7±5.67 nm and -45.72±3.24 mV, respectively. The TEM analysis also corroborated the particle size and shape, while thermal analysis (DSC) indicated that Gem was entrapped into NPs in an amorphous form. The nucleoside transport inhibition assay demonstrated that the NPs do not depend on transporters for cellular internalization, and hence, resistance development in cells is less expected against this formulation. HA-Gem-BSANPs exhibited higher cytotoxicity and apoptosis on both the tested cell lines. However, better cell-killing ability and mitochondrial membrane potential loss were observed against A549 due to CD44 expression.

Conclusion

The present work demonstrated that HA-Gem-BSANPs could be a potential strategy to improve Gem's therapeutic efficacy by selectively targeting the tumor site.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdd/10.2174/0115672018317615240926163652
2025-02-12
2025-05-03

  • From This Site

    /content/journals/cdd/10.2174/0115672018317615240926163652
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Liu C.G. Han Y.H. Kankala R.K. Wang S.Bin. Chen A.Z. Subcellular performance of nanoparticles in cancer therapy. Int. J. Nanomedicine 2020 15 675 704 10.2147/IJN.S226186
    [Google Scholar]
  2. Carmichael J. Fink U. Russell R.C. Spittle M.F. Harris A.L. Spiessi G. Blatter J. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer 1996 73 1 101 105 10.1038/bjc.1996.18
    [Google Scholar]
  3. Yardley D. Gemcitabine plus paclitaxel in breast cancer. Semin. Oncol. 2005 32 SUPPL. 6 14 21 10.1053/j.seminoncol.2005.06.025
    [Google Scholar]
  4. Ozols R. Gemcitabine and carboplatin in second-line ovarian cancer. Semin. Oncol. 2005 32 SUPPL. 6 4 8 10.1053/j.seminoncol.2005.06.023
    [Google Scholar]
  5. Hoang T. Kim K. Jaslowski A. Koch P. Beatty P. McGovern J. Quisumbing M. Shapiro G. Witte R. Schiller J.H. Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer. Lung Cancer 2003 42 1 97 102 10.1016/S0169‑5002(03)00273‑3
    [Google Scholar]
  6. Heinemann V. Xu Y.Z. Chubb S. Sen A. Plunkett W. Hertel L.W. Grindey G.B. Heinemann V. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: A mechanism of self-potentiation. Cancer Res. 1992 52 3 533 539
    [Google Scholar]
  7. Neff T. Blau C.A. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp. Hematol. 1996 24 11 1340 1346
    [Google Scholar]
  8. Mackey J.R. Mani R.S. Selner M. Mowles D. Young J.D. Belt J.A. Crawford C.R. Cass C.E. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 1998 58 19 4349 4357
    [Google Scholar]
  9. Dubey R.D. Alam N. Saneja A. Khare V. Kumar A. Vaidh S. Mahajan G. Sharma P.R. Singh S.K. Mondhe D.M. Gupta P.N. Development and evaluation of folate functionalized albumin nanoparticles for targeted delivery of gemcitabine. Elsevier B.V. 2015 Vol. 492 10.1016/j.ijpharm.2015.07.012
    [Google Scholar]
  10. Miele E. Spinelli G.P. Miele E. Tomao F. Tomao S. Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer. Int. J. Nanomedicine 2009 4 1 99 105 10.2147/ijn.s3061
    [Google Scholar]
  11. Green M.R. Manikhas G.M. Orlov S. Afanasyev B. Makhson A.M. Bhar P. Hawkins M.J. Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann. Oncol. 2006 17 8 1263 1268 10.1093/annonc/mdl104
    [Google Scholar]
  12. Dosio F. Arpicco S. Stella B. Fattal E. Hyaluronic acid for anticancer drug and nucleic acid delivery. Adv. Drug Deliv. Rev. 2016 97 204 236 10.1016/j.addr.2015.11.011
    [Google Scholar]
  13. Bregadze V.I. Sivaev I.B. Semioshkin A. Shmal’ko A.V. Kosenko I.D. Lebedeva K.V. Mandal S. Sreejyothi P. Sarkar A. Shen Z. Wu A. Hosmane N.S. Boron‐containing lipids and liposomes: New conjugates of cholesterol with polyhedral boron hydrides. Chem. A Eur. J. 2020 26 13832 13841 10.1002/chem.201905083
    [Google Scholar]
  14. Dubey R.D. Sarkar A. Shen Z. Bregadze V.I. Sivaev I.B. Druzina A.A. Zhidkova O.B. Shmal’ko A.V. Kosenko I.D. P S. Mandal S. Hosmane N.S. Effects of linkers on the development of liposomal formulation of cholesterol conjugated cobalt bis(dicarbollides). J. Pharm. Sci. 2021 110 3 1365 1373 10.1016/j.xphs.2020.12.017
    [Google Scholar]
  15. Dubey R.D. Saneja A. Qayum A. Singh A. Mahajan G. Chashoo G. Kumar A. Andotra S.S. Singh S.K. Singh G. Koul S. Mondhe D.M. Gupta P.N. PLGA nanoparticles augmented the anticancer potential of pentacyclic triterpenediol in vivo in mice. RSC Adv. 2016 6 78 74586 74597 10.1039/c6ra14929d
    [Google Scholar]
  16. Nahire R. Haldar M.K. Paul S. Ambre A.H. Meghnani V. Layek B. Katti K.S. Gange K.N. Singh J. Sarkar K. Mallik S. Multifunctional polymersomes for cytosolic delivery of gemcitabine and doxorubicin to cancer cells. Biomaterials 2014 35 24 6482 6497 10.1016/j.biomaterials.2014.04.026
    [Google Scholar]
  17. Wang Y. Fan W. Dai X. Katragadda U. Mckinley D. Teng Q. Tan C. Enhanced tumor delivery of gemcitabine via PEG-DSPE/TPGS mixed micelles. Mol. Pharm. 2014 11 4 1140 1150 10.1021/mp4005904
    [Google Scholar]
  18. Jia L. Zheng J.J. Jiang S.M. Huang K.H. Preparation, physicochemical characterization and cytotoxicity in vitro of gemcitabine-loaded PEG-PDLLA nanovesicles. World J. Gastroenterol. 2010 16 8 1008 1013 10.3748/wjg.v16.i8.1008
    [Google Scholar]
  19. Dubey R.D. Klippstein R. Wang J.T.W. Hodgins N. Mei K.C. Sosabowski J. Hider R.C. Abbate V. Gupta P.N. Al-Jamal K.T. Novel hyaluronic acid conjugates for dual nuclear imaging and therapy in CD44-expressing tumors in mice in vivo. Nanotheranostics 2017 1 1 59 79 10.7150/ntno.17896
    [Google Scholar]
  20. Paroha S. Verma J. Singh Chandel A.K. Kumari S. Rani L. Dubey R.D. Mahto A.K. Panda A.K. Sahoo P.K. Dewangan R.P. Augmented therapeutic efficacy of Gemcitabine conjugated self-assembled nanoparticles for cancer chemotherapy. J. Drug Deliv. Sci. Technol. 2022 76 103796 10.1016/J.JDDST.2022.103796
    [Google Scholar]
  21. Chen Z. Chen J. Wu L. Li W. Chen J. Cheng H. Pan J. Cai B. Hyaluronic acid-coated bovine serum albumin nanoparticles loaded with brucine as selective nanovectors for intra-articular injection. Int. J. Nanomedicine 2013 8 3843 3853 10.2147/IJN.S50721
    [Google Scholar]
  22. Kumar R. Singh M. Meena J. Singhvi P. Thiyagarajan D. Saneja A. Panda A.K. Hyaluronic acid - dihydroartemisinin conjugate: Synthesis, characterization and in vitro evaluation in lung cancer cells. Int. J. Biol. Macromol. 2019 133 495 502 10.1016/j.ijbiomac.2019.04.124
    [Google Scholar]
  23. Li J. Chen W. Wang H. Jin C. Yu X.J. Lu W.Y. Cui L. Fu D.L. Ni Q.X. Hou H.M. Preparation of albumin nanospheres loaded with gemcitabine and their cytotoxicity against BXPC-3 cells in vitro. Acta Pharmacol. Sin. 2009 30 9 1337 1343 10.1038/aps.2009.125
    [Google Scholar]
  24. Qi S. J W. McAuley Yang Z. Tipduangta P. Physical stabilization of low-molecular-weight amorphous drugs in the solid state: A material science approach. Ther. Deliv. 2014 5 7 817 841 10.4155/tde.14.39
    [Google Scholar]
  25. Gupta A. Asthana S. Konwar R. Chourasia M.K. An insight into potential of nanoparticles-assisted chemotherapy of cancer using gemcitabine and its fatty acid prodrug:a comparative study. J. Biomed. Nanotechnol. 2013 9 5 915 925 10.1166/jbn.2013.1591
    [Google Scholar]
  26. Bareford L.M. Swaan P.W. Endocytic Mechanisms for targeted drug delivery. Adv. Drug Deliv. Rev. 2007 59 8 748 758 10.1016/j.addr.2007.06.008
    [Google Scholar]
  27. Vandana M. Sahoo S.K. Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer. Biomaterials 2010 31 35 9340 9356 10.1016/j.biomaterials.2010.08.010
    [Google Scholar]
  28. Giovannetti E. Leon L.G. Bertini S. Macchia M. Minutolo F. Funel N. Alecci C. Giancola F. Danesi R. Peters G.J. Study of apoptosis induction and deoxycytidine kinase/cytidine deaminase modulation in the synergistic interaction of a novel ceramide analog and gemcitabine in pancreatic cancer cells. Nucleosides, Nucleotides and Nucleic Acids 2010 29 4-6 419 426 10.1080/15257771003730193
    [Google Scholar]
  29. Abbruzzese J.L. Grunewald R. Kantarjian H. Du M. Faucher K. Tarassoff P. Plunkett W. Gemcitabine in leukemia: A phase I clinical, plasma, and cellular pharmacology study. J. Clin. Oncol. 1992 10 3 406 413 10.1200/jco.1992.10.3.406
    [Google Scholar]
  30. Mey V. Giovannetti E. Braud F.D. Nannizzi S. Curigliano G. Verweij F. Cobelli O.D. Pece S. Tacca M.D. Danesi R. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br. J. Cancer 2006 95 3 289 297 10.1038/sj.bjc.6603242
    [Google Scholar]
  31. Berman P.A. Adams P.A. Artemisinin enhances heme-catalysed oxidation of lipid membranes. Free Radic. Biol. Med. 1997 22 7 1283 1288 10.1016/S0891‑5849(96)00508‑4
    [Google Scholar]
/content/journals/cdd/10.2174/0115672018317615240926163652
Loading
Fabrication and Evaluation of Hyaluronic Acid-Coated Albumin Nanoparticles for Delivery of Gemcitabine
Bentham Science Publishers ; https://doi.org/10.2174/0115672018317615240926163652
/content/journals/cdd/10.2174/0115672018317615240926163652
/content/journals/cdd/10.2174/0115672018317615240926163652
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: Gemcitabine ; bovine serum albumin ; mitochondrial membrane potential ; hyaluronic acid ; cytotoxicity ; nanoparticles ; anticancer ; CD44 receptor

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test